Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Interest Expenses (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Interest Expenses readings, the most recent being $11.4 million for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 4.43% to $11.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.2 million, a 6.93% decrease, with the full-year FY2025 number at $46.2 million, down 6.93% from a year prior.
  • Interest Expenses hit $11.4 million in Q4 2025 for Amicus Therapeutics, down from $11.7 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $13.0 million in Q3 2023 to a low of $8.0 million in Q1 2021.
  • Median Interest Expenses over the past 5 years was $11.5 million (2025), compared with a mean of $10.8 million.
  • Biggest five-year swings in Interest Expenses: soared 124.21% in 2021 and later decreased 7.89% in 2025.
  • Amicus Therapeutics' Interest Expenses stood at $8.2 million in 2021, then surged by 35.9% to $11.1 million in 2022, then increased by 15.61% to $12.8 million in 2023, then dropped by 6.77% to $12.0 million in 2024, then dropped by 4.43% to $11.4 million in 2025.
  • The last three reported values for Interest Expenses were $11.4 million (Q4 2025), $11.7 million (Q3 2025), and $11.6 million (Q2 2025) per Business Quant data.